CCL2 and metabolic dysfunction-associated steatohepatitis: Blockade of CD36 and CCL2 with neutralizing antibodies ameliorates the NASH progression in Mettl3-HKO mice, which further supports the theory that elevated CD36 and CCL2 contribute to the NASH progression in Mettl3-HKO mice.